Clinical utility of current NNRTIs and perspectives of new agents in this class under development

Antiviral Chemistry and Chemotherapy

Volumn 15, Issue 3, 2004, Pages 121-134

  Zhang, Zhijun ^a   Hamatake, Robert ^a   Hong, Zhi ^a  

^a Valeant Pharmaceuticals International   (United States)

Author keywords

Calanolide; Capravirine; Delavirdine; DPC 83; Efavirenz; GW8248; HIV 1; MKC 442; Nevirapine; NNRTIs; SJ 3366; TMC 125; UC 781

Indexed keywords

1 (3 CYCLOPENTENYLMETHYL) 6 (3,5 DIMETHYLBENZOYL) 5 ETHYLURACIL; 6 CHLORO 4 (2 CYCLOPROPYLVINYL) 3,4 DIHYDRO 4 TRIFLUOROMETHYL 2(1H) QUINAZOLINONE; ABACAVIR; AMPRENAVIR; CALANOLIDE A; CAPRAVIRINE; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; EMIVIRINE; ETRAVIRINE; GW 8248; INDINAVIR; LAMIVUDINE; N [4 CHLORO 3 (3 METHYL 2 BUTENYLOXY)PHENYL] 2 METHYL 3 FURANCARBOTHIOAMIDE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; UN 781; UNCLASSIFIED DRUG; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AGITATION; CAUSE OF DEATH; CLINICAL TRIAL; COGNITIVE DEFECT; CROSS RESISTANCE; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG EXCRETION; DRUG METABOLISM; DRUG STRUCTURE; DRUG USE; FEVER; GENE MUTATION; HEADACHE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INSOMNIA; LIVER DYSFUNCTION; LIVER TOXICITY; MENTAL DISEASE; METABOLIC DISORDER; NIGHTMARE; NONHUMAN; PATIENT COMPLIANCE; PILL; PRIORITY JOURNAL; QUALITY OF LIFE; RASH; REVIEW; SIDE EFFECT; STEVENS JOHNSON SYNDROME; TERATOGENICITY; VIVID DREAM;

EID: 2942704146     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632020401500302     Document Type: Review

References (87)

1. Albright AV, Erickson-Viitanen S, O'Connor M, Frank I, Rayner MM & Gonzalez-Scarano F (2000) Efavirenz is a potent nonnucleoside reverse transcriptase inhibitor of HIV type 1 replication in microglia in vitro. AIDS Research & Human Retroviruses 16:1527-1537.
2. Baba M, Shigeta S, Yuasa S, Takashima H, Sekiya K, Ubasawa M, Tanaka H, Miyasaka T, Walker RT & De Clercq E (1994) Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro. Antimicrobial Agents & Chemotherapy 38:688-692.
3. Baba M, Yuasa S, Niwa T, Yamamoto M, Yabuuchi S, Takashima H, Ubasawa M, Tanaka H, Miyasaka T, Walker RT, Balzarini J, De Clercq E & Shigeta S (1993) Effect of human serum on the in vitro anti-HIV-1 activity of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) derivatives as related to their lipophilicity and serum protein binding. Biochemical Pharmacology 45:2507-2512.
4. Bacheler L, Jeffrey S, Hanna G, D'Aquila R, Wallace L, Logue K, Cordova B, Hertogs K, Larder B, Buckery R, Baker D, Gallagher K, Scarnati H, Tritch R & Rizzo C (2001) Genotypic correlates of phenotypic resistance to efavirenz in virus isolates from patients failing nonnucleoside reverse transcriptase inhibitor therapy. Journal of Virology 75:4999-5008.
5. Bacheler LT, Anton ED, Kudish P, Baker D, Bunville J, Krakowski K, Bolling L, Aujay M, Wang XV, Ellis D, Becker MF, Lasut AL, George HJ, Spalding DR, Hollis G & Abremski K (2000) Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicrobial Agents & Chemotherapy 44:2475-2484.
6. Barnard J, Borkow G & Parniak MA (1997) The thiocarboxanilide nonnucleoside UC781 is a tight-binding inhibitor of HIV-1 reverse transcriptase. Biochemistry 36:7786-7792.
7. Barreiro P, Soriano V, Blanco F, Casimiro C, de la Cruz JJ & Gonzalez-Lahoz J (2000) Risks and benefits of replacing protease inhibitors by nevirapine in HIV-infected subjects under long-term successful triple combination therapy. AIDS 14:807-812.
8. Bell C, Matthews GV & Nelson MR (2003) Non-nucleoside reverse transcriptase inhibitors- an overview. International Journal of STD & AIDS 14:71-77.
9. BHIVA (2003) BHIVA Writing Committee. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Medicine 4 (Suppl 1):1-41. http://www.bhiva.org/guidelines/2003/hiv/index. html
10. Borkow G, Barnard J, Nguyen TM, Belmonte A, Wainberg MA & Parniak MA (1997) Chemical barriers to human immunodeficiency virus type 1 (HIV-1) infection: retrovirucidal activity of UC781, a thiocarboxanilide nonnucleoside inhibitor of HIV-1 reverse transcriptase. Journal of Virology 71:3023-3030.
11. Buckheit RW (2001) Non-nucleoside reverse transcriptase inhibitors: perspectives on novel therapeutic compounds and strategies for the treatment of HIV infection. Expert Opinion on Investigational Drugs 10:1423-1442.
12. Buckheit RW, Jr., Kinjerski TL, Fliakas-Boltz V, Russell JD, Stup TL, Pallansch LA, Brouwer WG, Dao DC, Harrison WA & Schultz RJ (1995) Structure-activity and cross-resistance evaluations of a series of human immunodeficiency virus type-1-specific compounds related to oxathiin carboxanilide. Antimicrobial Agents & Chemotherapy 39:2718-2727.
13. Buckheit RW, Jr., Watson K, Fliakas-Boltz V, Russell J, Loftus TL, Osterling MC, Turpin JA, Pallansch LA, White EL, Lee JW, Lee SH, Oh JW, Kwon HS, Chung SG & Cho EH (2001) SJ-3366, a unique and highly potent nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1 (HIV-1) that also inhibits HIV-2. Antimicrobial Agents & Chemotherapy 45:393-400.
14. Buckheit RW, Jr, White EL, Fliakas-Boltz V, Russell J, Stup TL, Kinjerski TL, Osterling MC, Weigand A & Bader JP (1999) Unique anti-human immunodeficiency virus activities of the nonnucleoside reverse transcriptase inhibitors calanolide A, costatolide, and dihydrocostatolide. Antimicrobial Agents & Chemotherapy 43:1827-1834.
15. Campiani G, Ramunno A, Maga G, Nacci V, Fattorusso C, Catalanotti B, Morelli E & Novellino E (2002) Non-nucleoside HIV-1 reverse transcriptase (RT) inhibitors: past, present and future perspectives. Current Pharmaceutical Design 8:615-657.
16. Conway B (2000) Initial therapy with protease inhibitor-sparing regimens: evaluation of nevirapine and delavirdine. Clinical Infectious Diseases 30 (Suppl 2):S130-S134.
17. Corbett JW, Ko SS, Rodgers JD, Gearhart LA, Magnus NA, Bacheler LT, Diamond S, Jeffrey S, Klabe RM, Cordova BC, Garber S, Logue K, Trainor GL, Anderson PS & Erickson-Viitanen SK (2000) Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors. Journal of Medicinal Chemistry 43:2019-2030.
18. Corbett JW, Ko SS, Rodgers JD, Jeffrey S, Bacheler LT, Klabe RM, Diamond S, Lai CM, Rabel SR, Saye JA, Adams SP, Trainor GL, Anderson PS & Erickson-Viitanen SK (1999) Expanded-spectrum nonnucleoside reverse transcriptase inhibitors inhibit clinically relevant mutant variants of human immunodeficiency virus type 1. Antimicrobial Agents & Chemotherapy 43:2893-2897.
19. Cozzi-Lepri A, Phillips AN, d'Arminio Monforte A, Piersantelli N, Orani A, Petrosillo N, Leoncini F, Scerbo A, Tundo P, Abrescia N & Moroni M (2002) Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naive Antiretrovirals (I.Co.N.A.) study. Journal of Infectious Diseases 185:1062-1069.
20. Creagh T, Ruckle JL, Tolbert DT, Giltner J, Eiznhamer DA, Dutta B, Flavin MT & Xu ZQ (2001) Safety and pharmacokinetics of single doses of (+)-calanolide a, a novel, naturally occurring nonnucleoside reverse transcriptase inhibitor, in healthy, human immunodeficiency virus-negative human subjects. Antimicrobial Agents & Chemotherapy 45:1379-1386.
21. Davey RT, Jr., Chaitt DG, Reed GF, Freimuth WW, Herpin BR, Metcalf JA, Eastman PS, Falloon J, Kovacs JA, Polis MA, Walker RE, Masur H, Boyle J, Coleman S, Cox SR, Wathen L, Daenzer CL & Lane HC (1996) Randomized, controlled phase I/II, trial of combination therapy with delavirdine (U-90152S) and conventional nucleosides in human immunodeficiency virus type 1-infected patients. Antimicrobial Agents & Chemotherapy 40:1657-1664.
22. De Clercq E (1999) Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection. Farmaco 54:26-45.
23. Deeks SG (2001) International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance. Journal of Acquired Immune Deficiency Syndrome 26 (Suppl 1):S25-33.
24. Demeter LM, Shafer RW, Meehan PM, Holden-Wiltse J, Fischl MA, Freimuth WW, Para MF & Reichman RC (2000) Delavirdine susceptibilities and associated reverse transcriptase mutations in human immunodeficiency virus type 1 isolates from patients in a phase I/II trial of delavirdine monotherapy (ACTG 260). Antimicrobial Agents & Chemotherapy 44:794-797.
25. DHHS Panel on Clinical Practices for Treatment of HIV Infection (2003) Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents http://www.aidsinfo.nih.gov/guidelines/adult/html
26. Ding J, Das K, Moereels H, Koymans L, Andries K, Janssen PA, Hughes SH & Arnold E (1995) Structure of HIV-1 RT/TIBO R 86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors. Nature Structural Biology 2:407-415.
27. Eiznhamer DA, Creagh T, Ruckle JL, Tolbert DT, Gilmer J, Dutta B, Flavin MT, Jenta T & Xu ZQ (2002) Safety and pharmacokinetic profile of multiple escalating doses of (+)-calanolide A, a naturally occurring nonnucleoside reverse transcriptase inhibitor, in healthy HIV-negative volunteers. HIV Clinical Trials 3:435-450.
28. Erickson DA, Mather G, Trager WF, Levy RH & Keirns JJ (1999) Characterization of the in vitro biotransformation of the HIV-1 reverse transcriptase inhibitor nevirapine by human hepatic cytochromes P-450. Drug Metabolism & Disposition 27:1488-1495.
29. Estrada V, De Villar NG, Larrad MT, Lopez AG, Fernandez C & Serrano-Rios M (2002) Long-term metabolic consequences of switching from protease inhibitors to efavirenz in therapy for human immunodeficiency virus-infected patients with lipoatrophy. Clinical Infectious Diseases 35:69-76.
30. Flavin MT, Rizzo JD, Khilevich A, Kucherenko A, Sheinkman AK, Vilaychack V, Lin L, Chen W, Greenwood EM, Pengsuparp T, Pezzuto JM, Hughes SH, Flavin TM, Cibulski M, Boulanger WA, Shone RL & Xu ZQ (1996) Synthesis, chromatographic resolution, and anti-human immunodeficiency virus activity of (+/-)-calanolide A and its enantiomers. Journal of Medicinal Chemistry 39:1303-1313.
31. Fletcher RS, Syed K, Mithani S, Dmitrienko GI & Parniak MA (1995) Carboxanilide derivative non-nucleoside inhibitors of HIV-1 reverse transcriptase interact with different mechanistic forms of the enzyme. Biochemistry 34:4346-4353.
32. Friedland GH, Pollard R, Griffith B, Hughes M, Morse G, Bassett R, Freimuth W, Demeter L, Connick E, Nevin T, Hirsch M & Fischl M (1999) Efficacy and safety of delavirdine mesylate with zidovudine and didanosine compared with two-drug combinations of these agents in persons with HIV disease with CD4 counts of 100 to 500 cell S/MM3 (ACTG 261). ACTG 261 Team. Journal of Acquired Immune Deficiency Syndrome 21:281-292.
33. Fujiwara T, Sato A, El-Farrash M, Miki S, Abe K, Isaka Y, Kodama M, Wu Y, Chen LB, Harada H, Sugimoto H, Hatanaka M & Hinuma Y (1998) S-1153 inhibits replication of known drug-resistant strains of human immunodeficiency virus type 1. Antimicrobial Agents & Chemotherapy 42:1340-1345.
34. Gazzard BG, Pozniak AL, Rosenbaum W, Yeni GP, Staszewski S, Arasteh K, De Dier K, Peeters M, Woodfall B, Stebbing J & Vant' Klooster GA (2003) An open-label assessment of TMC 125-a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRTI resistance. AIDS 17:F49-F54.
35. Gruzdev B, Rakhmanova A, Doubovskaya E, Yakovlev A, Peeters M, Rinehart A, De Dier K, Dijk PB, Parys W & Van't Klooster G (2003) A randomized, double-blind, placebo-controlled trial of TMC125 as 7-day monotherapy in antiretroviral naive, HIV-1 infected subjects. AIDS 17:2487-2894.
36. Guay LA, Musoke P, Fleming T, Bagenda D, Allen M, Nakabiito C, Sherman J, Bakaki P, Ducar C, Deseyve M, Emel L, Mirochnick M, Fowler MG, Mofenson L, Miotti P, Dransfield K, Bray D, Mmiro F & Jackson JB (1999) Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 354:795-802.
37. Harris M (2003) Efficacy and durability of nevirapine in antiretroviral-experienced patients. Journal of Acquired Immune Deficiency Syndrome 34 (Suppl 1):S53-S58.
38. Harris M & Montaner JS (2000) Clinical uses of non-nucleoside reverse transcriptase inhibitors. Reviews in Medical Virology 10:217-229.
39. Havlir D, Cheeseman SH, McLaughlin M, Murphy R, Erice A, Spector SA, Greenough TC, Sullivan JL, Hall D & Myers M (1995a) High-dose nevirapine: safety, pharmacokinetics, and antiviral effect in patients with human immunodeficiency virus infection. Journal of Infectious Diseases 171:537-545.
40. 3: AIDS Clinical Trials Group Protocol 208. Journal of Infectious Diseases 172:1379-1383.
41. Holmberg SD, Moorman AC, Williamson JM, Tong TC, Ward DJ, Wood KC, Greenberg AE & Janssen RS (2002) Protease inhibitors and cardiovascular outcomes in patients with HIV-1. Lancet 360:1747-1748.
42. Hopkins AL, Ren J, Tanaka H, Baba M, Okamato M, Stuart DI, & Stammers DK (1999) Design of MKC-442 (emivirine) analogues with improved activity against drug-resistant HIV mutants. Journal of Medicinal Chemistry 42:4500-4505.
43. Hsiou Y, Das K, Ding J, Clark AD, Jr., Kleim JP, Rosner M, Winkler I, Riess G, Hughes SH & Arnold E (1998) Structures of Tyr188Leu mutant and wild-type HIV-1 reverse transcriptase complexed with the non-nucleoside inhibitor HBY 097: inhibitor flexibility is a useful design feature for reducing drug resistance. Journal of Molecular Biology 284:313-323.
44. Hsiou Y, Ding J, Das K, Clark AD, Jr., Boyer PL, Lewi P, Janssen PA, Kleim JP, Rosner M, Hughes SH & Arnold E (2001) The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance. Journal of Molecular Biology 309:437-445.
45. Kashman Y, Gustafson KR, Fuller RW, Cardellina JH, 2nd, McMahon JB, Currens MJ, Buckheit RW, Jr, Hughes SH, Cragg GM & Boyd MR (1992) The calanolides, a novel HIV-inhibitory class of coumarin derivatives from the tropical rainforest tree, Calophyllum lanigerum. Journal of Medicinal Chemistry 35:2735-2743.
46. Kohlstaedt LA, Wang J, Friedman JM, Rice PA & Steitz TA (1992) Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256:1783-1790.
47. Kontorinis N & Dieterich DT (2003) Toxicity of non-nucleoside analogue reverse transcriptase inhibitors. Seminars in Liver Disease 23:173-182.
48. Koup RA, Merluzzi VJ, Hargrave KD, Adams J, Grozinger K, Eckner RJ & Sullivan JL (1991) Inhibition of human immunodeficiency virus type 1 (HIV-1) replication by the dipyridodiazepinone BI-RG-587. Journal of Infectious Diseases 163:966-970.
49. Lamson MJ, Sabo JP, MacGregor TR, Pav JW, Rowland L, Hawi A, Cappola M & Robinson P (1999) Single dose pharmacokinetics and bioavailability of nevirapine in healthy volunteers. Biopharmaceutics & Drug Disposition 20:285-291.
50. Leigh Brown AJ, Frost SD, Mathews WC, Dawson K, Hellmann NS, Daar ES, Richman DD & Little SJ (2003) Transmission fitness of drug-resistant human immunodeficiency virus and the prevalence of resistance in the antiretroviral-treated population. Journal of Infectious Diseases 187:683-686.
51. Manfredi R, Calza L & Chiodo F (2002) A prospective comparison of the two main indications of efavirenz in 2001 highly active antiretroviral therapy (HAART) regimens: first-line versus salvage use. Journal of Antimicrobial Chemotherapy 49:723-729.
52. Marseille E, Kahn JG, Mmiro F, Guay L, Musoke P, Fowler MG & Jackson JB (1999) Cost effectiveness of single-dose nevirapine regimen for mothers and babies to decrease vertical HIV-1 transmission in sub-Saharan Africa. Lancet 354:803-809.
53. Martinez E, Blanco JL, Arnaiz JA, Perez-Cuevas JB, Mocroft A, Cruceta A, Marcos MA, Milinkovic A, Garcia-Viejo MA, Mallolas J, Carne X, Phillips A & Gatell JM (2001a) Hepatotoxicity in HIV-1-infected patients receiving nevirapine-containing antiretroviral therapy. AIDS 15:1261-1268.
54. Martinez E, Conget I, Lozano L, Casamitjana R & Gatell JM (1999) Reversion of metabolic abnormalities after switching from HIV-1 protease inhibitors to nevirapine. AIDS 13:805-810.
55. Martinez E, Garcia-Viejo MA, Blanch L & Gatell JM (2001b) Lipodystrophy syndrome in patients with HIV infection: quality of life issues. Drug Safety 24:157-166.
56. Matthews GV, Sabin CA, Mandalia S, Lampe F, Phillips AN, Nelson MR, Bower M, Johnson MA & Gazzard BG (2002) Virological suppression at 6 months is related to choice of initial regimen in antiretroviral-naive patients: a cohort study. AIDS 16:53-61.
57. Merluzzi VJ, Hargrave KD, Labadia M, Grozinger K, Skoog M, Wu JC, Shih CK, Eckner K, Hattox S, Adams J, Rosehthal AS, Faanes R, Eckner RJ, Koup RA & Sullivan JL (1990) Inhibition of HIV-1 replication by a nonnucleoside reverse transcriptase inhibitor. Science 250:1411-1413.
58. Mirochnick M, Fenton T, Gagnier P, Pav J, Gwynne M, Siminski S, Sperling RS, Beckerman K, Jimenez E, Yogev R, Spector SA & Sullivan JL (1998) Pharmacokinetics of nevirapine in human immunodeficiency virus type 1-infected pregnant women and their neonates. Pediatric AIDS Clinical Trials Group Protocol 250 Team. Journal of Infectious Diseases 178:368-374.
59. Murphy RL, Sommadossi JP, Lamson M, Hall DB, Myers M & Dusek A (1999) Antiviral effect and pharmacokinetic interaction between nevirapine and indinavir in persons infected with human immunodeficiency virus type 1. Journal of Infectious Diseases 179:1116-1123.
60. Negredo E, Cruz L, Paredes R, Ruiz L, Fumaz CR, Bonjoch A, Gel S, Tuldra A, Balague M, Johnston S, Arno A, Jou A, Tural C, Sirera G, Romeu J & Clotet B (2002a) Virological, immunological, and clinical impact of switching from protease inhibitors to nevirapine or to efavirenz in patients with human immunodeficiency virus infection and long-lasting viral suppression. Clinical Infectious Diseases 34:504-510.
61. Negredo E, Ribalta J, Paredes R, Ferre R, Sirera G, Ruiz L, Salazar J, Reiss P, Masana L & Clotet B (2002b) Reversal of atherogenic lipoprotein profile in HIV-1 infected patients with lipodystrophy after replacing protease inhibitors by nevirapine. AIDS 16:1383-1389.
62. Para MF, Meehan P, Holden-Wiltse J, Fischl M, Morse G, Shafer R, Demeter LM, Wood K, Nevin T, Virani-Ketter N & Freimuth WW (1999) ACTG 260: a randomized, phase I-II, dose-ranging trial of the anti-human immunodeficiency virus activity of delavirdine monotherapy. The AIDS Clinical Trials Group Protocol 260 Team. Antimicrobial Agents & Chemotherapy 43:1373-1378.
63. Pedersen OS & Pedersen EB (1999) Non-nucleoside reverse transcriptase inhibitors: the NNRTI boom. Antiviral Chemistry & Chemotherapy 10:285-314.
64. Penzak SR, & Chuck SK (2000) Hyperlipidemia associated with HIV protease inhibitor use: pathophysiology, prevalence, risk factors and treatment. Scandinavian Journal of Infectious Diseases 32:111-123.
65. Perez-Molina JA (2002) Safety and tolerance of efavirenz in different antiretroviral regimens: results from a national multicenter prospective study in 1,033 HIV-infected patients. HIV Clinical Trials 3:279-286.
66. Perez-Molina JA, Perez Nr R, Miralles P, Cosin J, Padilla B, Berenguer J & Bouza E (2001) Nelfinavir plus nevirapine plus two NRTIS as salvage therapy for HIV-infected patients receiving long-term antiretroviral treatment. HIV Clinical Trials 2:1-5.
67. Podzamczer D, Ferrer E, Consiglio E, Gatell JM, Perez P, Perez JL, Luna E, Gonzalez A, Pedrol E, Lozano L, Ocana I, Llibre JM, Casiro A, Aranda M, Barrufet P, Martinez-Lacasa J, Miro JM, Badia X, Casado A, Lupo S, Cahn P, Manos M & Estela J (2002) A randomized clinical trial comparing nelfinavir or nevirapine associated to zidovudine/lamivudine in HIV-infected naive patients (the Combine Study). Antiviral Therapy 7:81-90.
68. Pollard RB, Robinson P & Dransfield K (1998) Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. Clinical Therapy 20:1071-1092.
69. Ren J, Milton J, Weaver KL, Short SA, Stuart DI & Stammers DK (2000) Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase. Structure with Folding & Design 8:1089-1094.
70. Ren J, Nichols C, Bird L, Chamberlain P, Weaver K, Short S, Stuart DI & Stammers DK (2001) Structural mechanisms of drug resistance for mutations at codons 181 and 188 in HIV-1 reverse transcriptase and the improved resilience of second generation nonnucleoside inhibitors. Journal of Molecular Biology 312:795-805.
71. Richman DD, Havlir D, Corbeil J, Looney D, Ignacio C, Spector SA, Sullivan J, Cheeseman S, Barringer K, Pauletti D, Shih C-K, Myers M & Griffin J (1994) Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. Journal of Virology 68:1660-1666.
72. Riska PS, Joseph DP, Dinallo RM, Davidson WC, Keirns JJ & Hattox SE (1999) Biotransformation of nevirapine, a non-nucleoside HIV-1 reverse transcriptase inhibitor, in mice, rats, rabbits, dogs, monkeys, and chimpanzees. Drug Metabolism & Disposition 27:1434-1447.
73. Robbins GK, De Gruttola V, Shafer RW, Smeaton LM, Snyder SW, Pettinelli C, Dube MP, Fischl MA, Pollard RB, Delapenha R, Gedeon L, van der Horst C, Murphy RL, Becker MI, D'Aquila RT, Vella S, Merigan TC & Hirsch MS (2003) Comparison of sequential three-drug regimens as initial therapy for HIV-1 infection. New England Journal of Medicine 349:2293-22303.
74. Ruiz L, Negredo E, Domingo P, Paredes R, Francia E, Balague M, Gel S, Bonjoch A, Fumaz CR, Johnston S, Romeu J, Lange J & Clotet B (2001) Antiretroviral treatment simplification with nevirapine in protease inhibitor-experienced patients with HIV-associated lipodystrophy: 1-year prospective follow-up of a multicenter, randomized, controlled study. Journal of Acquired Immune Deficiency Syndromes 27:229-236.
75. Sankatsing SU, Weverling GJ, Peeters M, Van't Klooster G, Gruzdev B, Rakhmanova A, Danner SA, Jurriaans S, Prins JM & Lange JM (2003) TMC125 exerts similar initial antiviral potency as a five-drug, triple class antiretroviral regimen. AIDS 17:2623-2627.
76. Scott LJ & Perry CM (2000) Delavirdine: a review of its use in HIV infection. Drugs 60:1411-1444.
77. Shelton MJ, Hewitt RG, Adams J, Della-Coletta A, Cox S & Morse GD (2003) Pharmacokinetics of ritonavir and delavirdine in human immunodeficiency virus-infected patients. Antimicrobial Agents & Chemotherapy 47:1694-1699.
78. Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A, Skiest D, Stanford J, Stryker R, Johnson P, Labriola DF, Farina D, Manion DJ & Ruiz NM (1999) Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. New England Journal of Medicine 341:1865-1873.
79. Sullivan AK, Nelson MR, Shaw A, Moyle GJ, Mandalia S, Gazzard BG & Asboe D (2000) Efficacy of a nelfinavir- and nevirapine-containing salvage regimen. HIV Clinical Trials 1:7-12.
80. Szczech GM, Furman P, Painter GR, Barry DW, Borroto-Esoda K, Grizzle TB, Blum MR, Sommadossi J, Endoh R, Niwa T, Yamamoto M & Moxham C (2000) Safety assessment, in vitro and in vivo, and pharmacokinetics of emivirine, a potent and selective nonnucleoside reverse transcriptase inhibitor of human immunodeficiency virus type 1. Antimicrobial Agents & Chemotherapy 44:123-130.
81. Tashima KT, Caliendo AM, Ahmad M, Gormley JM, Fiske WD, Brennan JM & Flanigan TP (1999) Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV-1-infected patients receiving combination therapy. Journal of Infectious Diseases 180:862-864.
82. Tran JQ, Petersen C, Garrett M, Hee B & Kerr BM (2002) Pharmacokinetic interaction between amprenavir and delavirdine: evidence of induced clearance by amprenavir. Clinical Pharmacology & Therapeutics 72:615-626.
83. van Heeswijk RP, Veldkamp AI, Mulder JW, Meenhorst PL, Wit FW, Lange JM, Danner SA, Foudraine NA, Kwakkelstein MO, Reiss P, Beijnen JH & Hoetelmans RM (2000) The steady-state pharmacokinetics of nevirapine during once daily and twice daily dosing in HIV-1-infected individuals. DAIDS 14:F77-F82.
84. Van Herrewege Y, Michiels J, Van Roey J, Fransen K, Kestens L, Balzarini J, Lewi P, Vanham G & Janssen P (2004) In vitro evaluation of nonnucleoside reverse transcriptase inhibitors UC-781 and TMC120-R147681 as human immunodeficiency virus microbicides. Antimicrobial Agents & Chemotherapy 48:337-339.
85. van Leeuwen R, Katlama C, Murphy RL, Squires K, Gatell J, Horban A, Clotet B, Staszewski S, van Eeden A, Clumeck N, Moroni M, Pavia AT, Schmidt RE, Gonzalez-Lahoz J, Montaner J, Antunes F, Gulick R, Banhegyi D, van der Valk M, Reiss P, van Weert L, van Leth F, Johnson VA, Sommadossi JP & Lange JM (2003) A randomized trial to study first-line combination therapy with or without a protease inhibitor in HIV-1-infected patients. AIDS 17:987-999.
86. Wainberg MA (2003) HIV resistance to nevirapine and other nonnucleoside reverse transcriptase inhibitors. Journal of Acquired Immune Deficiency Syndrome 34 (Suppl. 1):S2-S7.
87. Zussman A, Lara L, Lara HH, Bentwich Z & Borkow G (2003) Blocking of cell-free and cell-associated HIV-1 transmission through human cervix organ culture with UC781. AIDS 17:653-661.